Merck & Co., Inc. today announced that the U.S. Centers for Disease Control and Prevention (CDC) has added Merck's cervical cancer vaccine, GARDASIL® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] to the CDC's Vaccines for Children (VFC) contract for girls and women aged 9 to 18. [click link for full article]
More...